This trial is evaluating whether Lenvatinib will improve 2 primary outcomes and 4 secondary outcomes in patients with Neuroendocrine Tumors. Measurement will happen over the course of 2 years.
This trial requires 50 total participants across 1 different treatment group
This trial involves a single treatment. Lenvatinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"About 50% more people get neuroendocrine cancers a year than get tumors of the non-neuroendocrine organs. In total, over 1,500 cases of neuroendocrine tumor will be diagnosed, mostly gastrointestinal lesions in women and men. The greatest risk of death from neuroendocrine cancer is for patients with small bowel or gastrinoma." - Anonymous Online Contributor
"Neuroendocrine tumors typically can be treated by surgery, medication, radiotherapy or radioimmunotherapy if the tumor is well differentiated, resectable and locally advanced. Chemotherapy has become an alternative in patients with tumors in which more intensive surgical and medical management is not possible. Adjuvant radiotherapy can also improve survival, provided that the patient is well-selected. Finally, targeted treatments such as targeted therapies (such as sunitinib for GIST) or antiangiogenic agents (such as bevacizumab, aflibercept, sorafenib, sunitinib for GIST) are being utilized to treat metastatic or unresectable tumors." - Anonymous Online Contributor
"Neuroendocrine tumors arise from cells that line the nerves or the endocrine glands. They often produce hormones that regulate hormone signaling from other cells in the body. Neuroendocrine tumors may also arise from cells that do not line nerve or endocrine cells but are derived from these cells as they mature. Examples of neuroendocrine tumors are medullary thyroid carcinoma which arises from cells that line the lining of the thyroid follicle, and parathyroid adenoma which arises from parathyroid cells that line the parathyroid gland. They are the most common tumors in all cancers of the endocrine system." - Anonymous Online Contributor
"These patients with nonfunctional, well-differentiated NET in various organs are asymptomatic and are diagnosed by biopsy. Many patients suffer from severe headaches, and some may present with features suggestive of functional gastrointestinal or renal tumors or may suffer from anemia." - Anonymous Online Contributor
"Neuroendocrine tumor type is influenced by patient sex, age, and location. In particular, the presence and type of co-existent endocrine disease, the age of patient at diagnosis, and local site can affect site-specific tumor behavior and prognosis." - Anonymous Online Contributor
"Although rare, a subset of PNET have a remarkable potential for cure. In particular, patients with "intermediate" or "high-grade" type are at high risk. These patients require a full surgical staging procedure and, for high-grade patients, some chemotherapeutic adjuvant protocols." - Anonymous Online Contributor
"These data reveal that neuroendocrine tumors typically spread to extrapancreatic sites. However, the sites to which tumors metastasize varies depending on particular tumor types and patients." - Anonymous Online Contributor
"There's a lot of research on neuroendocrine tumors to support the research of medical professionals for treatment and prevention of neuroendocrine tumors. You can find the most recent research from [Power(http://www.withpower.com/clinictrials)] and [ScienceWatch"" - Anonymous Online Contributor
"In this first randomized phase III trial in this population, a 20% increase in median PFS was noted compared to a placebo with lenvatinib monotherapy. Median PFS, OS, and ORRs with lenvatinib were comparable to a placebo for patients with advanced NETs." - Anonymous Online Contributor
"Although neuroendocrine tumors usually develop from endocrine cells, neuroendocrine tumors may alternatively arise de novo or persist as the neoplasm of a benign precursor cell; neuroendocrine tumor subtypes can arise de novo or develop from other neoplasms. Genetic and epigenetic alterations may play an important role in either de novo development or persistence of neuroendocrine tumors." - Anonymous Online Contributor
"Lenvatinib has been shown to reduce or eliminate the expression of IGF1R, PDGFR-alpha, PDGFR-beta, and EGFR in cultured tumor cell lines. In mice, lenvatinib reduces tumor growth, causes regression of established tumors, lowers tumor vascularity, inhibits angiogenesis, and reduces intratumoral macrophage populations that are associated with angiogenesis. All of these findings suggest that lenvatinib may be effective for treating malignant tumors in humans regardless of the tumor subtype." - Anonymous Online Contributor
"Lenvatinib is being evaluated in clinical trials for several different indications, and the drug's mode of action is similar to gandertsartan, in the sense that the drug inhibits VEGFR2." - Anonymous Online Contributor